News and Announcements

GSK's RSV vaccine accepted for regulatory review by EMA

By Iain Gilbert

Date: Friday 13 Jun 2025

(Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.
The FTSE 100-listed group noted that Arexvy was the first RSV vaccine approved in the European Economic Area...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page